Biphenyl

Biphenyl

SCHEMBL3596635

BrCBr.c1ccc(-c2ccccc2)cc1

nearest known ligand 0.69

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.69
MAPK1 P28482 3/20 0.56
TSHR P16473 2/20 0.50
PTPN1 P18031 1/20 0.50
GSK3B P49841 1/20 0.50
TRPA1 O75762 1/20 0.50
TAAR1 Q96RJ0 3/20 0.48
TDP1 Q9NUW8 3/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
HSD17B10 Q99714 1/20 0.47
NOTUM Q6P988 1/20 0.47
MMP3 P08254 1/20 0.47
BCL2L1 Q07817 1/20 0.47
CRHBP P24387 1/20 0.43
CRHR2 Q13324 1/20 0.43
ATM Q13315 1/20 0.43
SLC22A2 O15244 1/20 0.43
SLC22A1 O15245 1/20 0.43
SLC22A3 O75751 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Biphenyl SCHEMBL8310031 0.86 ALDH1A1 (0.60) ALDH1A1MAPK1TSHRPTPN1GSK3B
Biphenyl SCHEMBL29008551 0.83 ALDH1A1 (1.00) ALDH1A1MAPK1TAAR1TDP1CYP1A2
Biphenyl SCHEMBL1358618 0.83 ALDH1A1 (1.00) ALDH1A1MAPK1TAAR1TDP1CYP1A2
SCHEMBL30629023 0.83 ALDH1A1 (1.00) ALDH1A1MAPK1TAAR1TDP1CYP1A2
Biphenyl SCHEMBL164 0.83 ALDH1A1 (1.00) ALDH1A1MAPK1TAAR1TDP1CYP1A2
Biphenyl SCHEMBL28890607 0.83 ALDH1A1 (1.00) ALDH1A1MAPK1TAAR1TDP1CYP1A2
Biphenyl SCHEMBL4002609 0.83 ALDH1A1 (1.00) ALDH1A1MAPK1TAAR1TDP1CYP1A2
Biphenyl SCHEMBL2548048 0.83 ALDH1A1 (1.00) ALDH1A1MAPK1TAAR1TDP1CYP1A2
SCHEMBL30108088 0.83 ALDH1A1 (1.00) ALDH1A1MAPK1TAAR1TDP1CYP1A2
SCHEMBL29560186 0.83 ALDH1A1 (1.00) ALDH1A1MAPK1TAAR1TDP1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102206208-A Preparation method for olmensartan medoxomil with low-level impurity SHANGHAI MODERN PHARMACEUTICAL CO LTD 2011-10-05 CN disclosed
US-20100076200-A1 Purification of olmesartan medoxomil HEDVATI LILACH 2010-03-25 US disclosed
US-7528258-B2 Preparation of olmesartan medoxomil TEVA PHARMACEUTICAL INDUSTRIES LTD (IL) 2009-05-05 US disclosed
EP-1784398-A1 PURIFICATION OF OLMESARTAN MEDOXOMIL Teva Pharmaceutical Industries Ltd (IL) 2007-05-16 EP disclosed
US-20070054948-A1 Purification of olmesartan medoxomil TEVA PHARMACEUTICALS USA, INC. 2007-03-08 US disclosed
EP-1716138-A1 PROCESS FOR PREPARING OLMESARTAN MEDOXOMIL AT PH HIGHER THAN 2.5 Teva Pharmaceutical Industries Ltd (IL) 2006-11-02 EP disclosed
EP-1706401-A1 PREPARATION OF OLMESARTAN MEDOXOMIL TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2006-10-04 EP disclosed
WO-2006073518-A1 PROCESS FOR PREPARING OLMESARTAN MEDOXOMIL AT PH HIGHER THAN 2.5 TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2006-07-13 WO disclosed
US-20060148870-A1 Process for preparing olmesartan medoxomil AT pH higher than 2.5 TEVA PHARMACEUTICALS USA, INC. 2006-07-06 US disclosed
US-20060074117-A1 Purification of olmesartan medoxomil TEVA PHARMACEUTICALS USA, INC. 2006-04-06 US disclosed
US-20060069141-A1 Preparation of olmesartan medoxomil TEVA PHARMACEUTICALS USA, INC. 2006-03-30 US disclosed
WO-2006029057-A1 PURIFICATION OF OLMESARTAN MEDOXOMIL TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) 2006-03-16 WO disclosed
WO-2006029056-A1 PREPARATION OF OLMESARTAN MEDOXOMIL TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2006-03-16 WO disclosed
CN-1219799-C Preparation method of vinyl polymer whose terminal has functional group SEKISUI CHEMICAL CO LTD (JP) 2005-09-21 CN disclosed
CN-1495201-A Preparation method of vinyl polymer whose terminal has functional group 积水化学工业株式会社 2004-05-12 CN disclosed
CN-1137907-C Method for producing vinyl polymer having functional group at terminal, and vinyl polymer having functional group at terminal 积水化学工业株式会社 2004-02-11 CN disclosed
CN-1346374-A Method for producing vinyl polymer having functional group at terminal, and vinyl polymer having functional group at terminal SEKISUI CHEMICAL CO LTD (JP) 2002-04-24 CN disclosed
US-4420595-A Process for the preparation of copolymers of ethylene with at least one other 1-alkene STAMICARBON B.V. (NL) 1983-12-13 US disclosed
EP-0044595-A1 Process for the preparation of copolymers of ethylene with at least one other 1-alkene STAMICARBON B.V. (NL) 1982-01-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148870-A1 Process for preparing olmesartan medoxomil AT pH higher than 2.5 AGTR2, AGTR1, NOX5 ALDH1A1 1287/4885MAPK1 519/4885TSHR 4315/4885
US-20070054948-A1 Purification of olmesartan medoxomil AGTR2, AGTR1, REN ALDH1A1 2331/4885MAPK1 1345/4885TSHR 3075/4885
US-20060074117-A1 Purification of olmesartan medoxomil AGTR2, AGTR1, REN ALDH1A1 2182/4885MAPK1 1359/4885TSHR 3396/4885
US-20100076200-A1 Purification of olmesartan medoxomil AGTR2, AGTR1, REN ALDH1A1 2182/4885MAPK1 1359/4885TSHR 3396/4885
US-20060069141-A1 Preparation of olmesartan medoxomil AGTR2, CYP4A11, AGTR1 ALDH1A1 2271/4885MAPK1 859/4885TSHR 3253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.